# 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

> **NCT06852820** · PHASE2 · RECRUITING · sponsor: **Melissa Lumish** · enrollment: 10 (estimated)

## Conditions studied

- Liver Cancer
- Hepatocellular Carcinoma
- Metastatic Liver Cancer

## Interventions

- **DRUG:** Lu-PSMA-617

## Key facts

- **NCT ID:** NCT06852820
- **Lead sponsor:** Melissa Lumish
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06852820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06852820, "68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06852820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*